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Introduction
Epidemiological data from the Framingham
Heart Study indicate that the cumulative incidence of
Atrial Fibrillation (AF) over a 22 year follow up was
2.1% in men and 1.7% in women.1 The prevalence of
AF increases with age, doubling with each successive
decade, and 70% of people with AF are between 65
and 85 years old. Furthermore, even after adjusting for
age and other risk factors, recent data suggest that the
prevalence of AF is increasing. AF is associated with a
3- to 5-fold increased risk of stroke, a 3-fold increased
risk of congestive heart failure and a significant 1.5- to
1.9-fold mortality risk after adjusting for underlying
cardiovascular conditions. It is not surprising that pacing
therapy which deals mainly with an elderly population
is involved with the management of concomitant AF in
a significant proportion of patients. Pacing therapy has
naturally been extended to the population with AF alone.

Consequence

maintenance of sinus rhythm and anticoagulation. While
rate control and anticoagulation are recognized
treatment, the efficacy and safety for Class I antiarrhythmic agents used to maintain sinus rhythm are
controversial. Proarrhythmias remains a concern with
Class I agents for AF. Low dose amiodarone, when
compared to either sotalol or propafenone, is more
efficacious in maintaining sinus rhythm.2 However, in
one study, amiodarone had to be discontinued for
cardiac and non-cardiac side effects in 18% of patients,
while 35% of patients still developed AF at 16 months.
While the development of newer anti-arrhythmic agents
may enhance our success in refractory cases, the current
experience underscores the difficulties of long term
pharmacological therapy alone to maintain sinus
rhythm. Indeed, the preliminary results of the AFFIRM
trial did not show the superiority of rhythm maintenance
using drugs over rate control alone (late breaking news,
America College of Cardiology Meeting, 2002). Thus,
the use of pacing, either alone or in hybrid fashion with
other therapies, has recently gained favour for treating
AF.

Pharmacotherapy for AF: How Successful Are
We?

Mechanisms of Pacing
Prevention of AF

Conventional pharmacological therapy includes
rate control with atrioventricular (AV) nodal blockers,
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AF develops as a result of the interaction between
the triggers (atrial premature beat, APB), the substate
(atrial effective refractory period and conduction
velocity) and mediation by the autonomic nervous
system. Tse et al3 examined the onset pattern of AF
during intracardiac electrophysiology study. This study
showed essentially 3 patterns of APB-induced AF onset:
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APBs that initiate AF after a pause, closely coupled
APB and short-long-short cycle of APB preceding AF.
Corresponding with observations from Holter
recordings, the coupling interval is shorter for APB
inducing AF compared to those that do not (Table 1).
In addition, a significant proportion of AF recurs within
minutes of restoration of sinus rhythm. Thus, pacing
therapy can be targeted to atrial overdrive suppression
of AF-inducing APBs, either by pacing at a shorter cycle
length or by applying specific algorithms based on the
APB coupling characteristics. Interestingly, most data
suggest that the prevailing sinus rate prior to the onset
of AF was normal or only slightly faster than normal in
over 80% of episodes. Thus a single rate support
algorithm to prevent bradycardia is unlikely to be
effective to suppress AF in the majority of cases. Apart
from initiating AF, APBs arising from the pulmonary
veins may also act as a perpetuator of AF, and high rate
overdrive pacing especially after AF termination may
be useful to suppress AF re-initiation.
Atrial electrical remodeling occurs with
sustained AF, leading to a shortening of AERP and
slowing of CV. 4 AERP shortens when AF lasts for
more than 5 minutes. Shortening of AERP and
prolonging CV promote further AF (AF begets AF).
This is further complicated by inhomogeneous

remodeling of different parts of the atrium such that
the left atrium had a more shortened AERP than the
lower right atrium (RA), along with a prolonged
interatrial conduction time and suppressed sinus node
function.5 Pacing, particularly using multi-sites or by
preexciting the abnormal tissues may homogenize the
electrical properties of the atrium and promote sinus
rhythm. One study 6 proposed that distal coronary
sinus (CS) pacing suppressed APB inducing AF by
limiting their prematurity at the Triangle of Koch,
which is a region of local conduction delay and
reentry. Simultaneous RA and distal CS pacing
reduced atrial conduction delay and increased
electrogram width at this region and could prevent
AF.7 By overdrive atrial pacing after AF, pacing may
avoid AERP dispersion mediated by abrupt cycle
length changes, thereby allowing time for reverse
atrial remodeling to occur before AF is re-initiated.
Very little is written on the role of autonomic
nervous system on AF mediation. A vagally mediated
type of AF has been described, and overdrive pacing
suppresses AF by counteracting bradycardia. 8 A
vagolytic effect of pacing the carotid sympathetic
chain has been suggested to suppress certain type of
AF in animals. Its role in humans remained to be
determined as a future target for AF therapy.

Table 1. Characteristics of AF onset
References
Killip (1965)
Bernett (1970)
Capucci (1992)
Murgatroyd (1993)
Mehra (1996)
Tse (1999)

No of episodes (patients)
18 (14)
32 (8)
168 (20)
1126 (78)
193 (80)
58 (53)

Preceding sinus rate
Fast Normal
Slow
NA
NA
15%
77%
8%
8.5%
82.8%
8.7%
12%
79%
9%
0%
91%
9%

APB coupling interval
AF (ms) No-AF (ms)
0.48*
0.68*
300
371
412
470
432
806
333
396

* Ratio of APB coupling interval to preceeding sinus cycle length
Killip T, et al. Am Heart J 1965;70:172.
Bernett MA, et al. Circulation 1970;41:981.
Capucci A, et al. Int J Cardiol 1992;36:87.
Murgatroyd F, et al. PACE 1993;16:1927.
Mehra R, Hill MRS. Prevention of atrial fibrillation/flutter by pacing techniques. In Saksena S, Luderitiz B, (eds). Interventional Electrophysiology: A text
Book. Second edition, Armonk, NY. Futura Publishing Company, Inc. 1996, Chapter 34, P521-40.
Tse HF, et al. Heart 1999;82:319-24.
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How Can Pacing Be Delivered?
Pacing can be delivered either in a passive or an
active manner (Figure) at a variety of sites. If AF
develops in a patient with a dual chamber pacemaker
(DDD), tracking of atrial activity may cause a rapid
ventricular response up to the programmed maximum
rate. Modern pacemakers respond to the arrhythmia by
activating an automatic mode switching algorithm.
When AF is detected or diagnosed, the pacemaker
converts automatically to a non-atrial tracking mode
(e.g. DDI or VVI), thereby preventing rapid ventricular
rates. A clinically proven strategy to treat medically
refractory AF is the use of AV nodal ablation followed
by permanent DDD(R) or VVI(R) pacing. This is
effectively a type of AF rate control and pacing does
not influence the AF itself. Standard support pacing has

also been tried in sinus node disease (SSS) and
bradycardia dependent AF.
Active pacing involves either fixed or dynamic
(based on the current sinus or a sensor mediated rate)
overdrive of the normal sinus rhythm. Active pacing
intervention using algorithms to counteract the mode
of APB onset have been developed to prevent these
APBs to initiate AF. An irregular ventricular rate in AF
contributes to adverse symptoms and hemo-dynamics,
and ventricular rate at a rate slightly faster than the
average ventricular pacing rate in AF (known as
ventricular regularization pacing) can be used to
achieved rate regularization.
Alternative atrial pacing sites different from the
conventional RA appendage or high lateral RA have
been evaluated to modify the underlying substrate.
Pacing has also been delivered from more than one site

Figure. Passive and active delivery of pacing therapy for AF.
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in the atrium. It is intuitive that some form of overdrive
rate rather than a standard pacing rate will be necessary
to maximize the "dose" of pacing to these sites, making
them a form of active pacing therapy.
Pacing for AF prevention has been applied to the
following patient populations: (1) SSS, (2) Pacing after
AV nodal ablation, (3) Vagally/bradycardia-related AF,
(4) AF with or without sinus bradycardia, and (5) AF
after cardiac surgery. Additionally, pacing methods are
now being used to terminate AF precursors, and to
control rate and irregularity once AF develops.

Automatic Mode Switching
Automatic Mode Switching (AMS) is a classic
example of how a dual chamber pacemaker can
passively handle AF. AF is detected in these pacemakers
when the atrial rate exceeds a certain programmable
limit, or a sensor defined rate limit, or a moving average
of the prevailing sinus rate. A study of 48 patients with
pacemakers incorporating, automatic mode switching
demonstrated objective improvement measured by
exercise capacity, subjective well being and functional
class over VVIR pacing and dual chamber pacing
without this algorithm.9 In addition, the type of mode
switching response (fast or slow) appears to be
important to maximize benefits. As the instrumentation
in the pacemaker is essentially software-based, most
pacemakers now have an automatic mode switching
algorithm as a programmable feature because of the
high prevalence of AF in the pacing population.

Pacing after AV Nodal Ablation
One of the most effective ways to treat the fast
and irregular rate of AF is provided by catheter AV
nodal ablation and implant a pacemaker to control the
patient's rhythm. Several studies have documented the
use of this "ablate and pace" strategy in improving
symptoms, heart failure, and well being of patients and
its superiority over conventional drug treatment.10 In
the North American registry that prospectively collected
74

156 patients followed up for 1 year, 11 sustained
improvement in quality of life was observed. Also, left
ventricular ejection fraction was improved in those with
a low ejection fraction (<45%).
One disadvantage of this strategy is pacemaker
dependence, with the need of replacement and
associated morbidity. In addition, there is a high
incidence of progression to permanent AF, likely to be
due to withdrawal of anti-arrhythmic agents. For
example, in one study, 10 AF developed in 24% of
patients in 6 months after "ablate and pace", but in none
of the controls in the continued drug arm. A mortality
rate of 15% with 3% of patients dying suddenly was
reported.11 This probably reflects the associated cardiac
problems rather than the procedure itself. A recent report
suggests that in the absence of previous myocardial
infarction, congestive cardiac failure and the use of
cardiac medications after pacing, patients after ablate
and pace had similar survival as age and sex matched
population when followed up for 3 years.12 With these
data are encouraging, the ablate and pace should still
be considered as the last therapeutic strategy.
A DDDR device is commonly prescribed after
AV nodal ablation, together with automatic mode
switching to avoid rapid ventricular tracking of AF.
Arguably, because of poor long term sinus maintenance
in this resistant group of patients, and in patients with
persistent AF prior to ablation, a VVIR device may be
an alternative.

Vagally/Bradycardia-mediated AF
Coumel et al13 reported a group of patients with
AF episodes with a characteristic pattern of onset. These
episodes typically occur after meals or exercise, or
during sleep and after prolonged sinus pauses.
Avoidance of provoking circumstances, the use of Class
1c agents like propafenone are recommended treatment.
Beta-blockers should be avoided as they may aggravate
the associated bradycardia. Pacing to prevent
bradycardia has been tried. In 4/6 patients, atrial pacing
prevented these AF episodes during a 5.5 years of
follow-up.13 Attuel et al8 used DDD pacing in 10 patients
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with SSS in whom AF onset was related to bradycardia,
and 7/10 patients also exhibited interatrial conduction
delay that was reversed with higher rate atrial pacing.
By overdrive pacing at a rate slightly above the mean
diurnal rate, this group reported successful control of
AF. Both studies suggest that in a small group of patients
in whom AF was clearly related to bradycardia, atrial
based pacing could be effective in preventing AF
episodes.

ventricular pacing in order to minimize the incidence
of AF. The impact of pacemaker prescription on AF
incidence in complete AV block is less certain, and is
the subject of several on-going studies (e.g. UK PACE).
As a high percentage of patients developed AF even
with atrial pacing, some would advocate prophylactic
use of additional strategies (hardware and software) to
combat future AF episodes. These are described below.

AF With or Without
Associated Bradycardia

SSS
AF occurs in a significant proportion of patients
with SSS after pacing. Connolly et al14 reviewed 10
retrospective studies comparing the use of atrial versus
ventricular pacing in patients was associated with SSS.
Atrial pacing is significantly associated with a lower
incidence of AF compared to ventricular pacing (6.8 vs
2.6% annually). In 3 prospective randomized studies,
AF is also reduced by atrial pacing. In the Danish study,15
225 patients with SSS were randomized to either single
chamber atrial (AAI) pacing or ventricular (VVI) pacing,
with a follow up of 8 years. The relative risk for AF
(0.35 vs 0.54), thromboembolic event, heart failure were
lower with AAI pacing, with a trend to better survival
in the AAI group. Similarly, on the other hand, in the
Canadian study that involved 1474 patients randomized
to VVI (R) pacing and 1094 to an atrial based pacemaker,
the annual rate of AF was reduced from 6.6% to 5.5%
with physiological pacing, or a relative risk reduction
of AF of 18% by 3 years. The effect on AF was only
apparent after 2 years. There was a trend for all cause
mortality, heart failure and hospitalization. In the elderly
population, DDD systems also improved quality of life
and reduced the progression to chronic AF.16 However,
in all of these studies, conventional pacing is used and a
control group is not possible as all of the involved
patients required pacing therapy. It can be argued that
atrial pacing does not actually suppress AF, rather, it is
ventricular pacing that is proarrhythmogenic.
Nevertheless, both retrospective and prospective
data teach us that when prescribing pacemaker therapy
for SSS, an atrial based pacing mode is preferred to
J HK Coll Cardiol, Vol 11

There are several situations in which a pacemaker
is used in patients with AF. PAF is present in about
half and one-third of patients with SSS and AV block
respectively at the time of pacing implantation.17 High
dose anti-arrhythmic medications can depress sinus
node function that requires pacing backup, and this is
now increasingly an indication for pacing in many
centres. In refractory cases, some would argue to
implant a pacemaker first, and delay or avoid AV nodal
ablation if AF can be controlled with a device. The above
categories of patients represent the largest body of data
on which pacing therapy has been tested, either alone
or more often in combination with anti-arrhythmic
medications. Finally, a device to treat AF in patients
without bradycardia is now being tested in several
clinical studies.

Conventional Pacing
In patients with medically refractory PAF
pending for AV nodal ablation, the PA3 study (Atrial
Pacing Periablation for Paroxysmal AF Study)
randomized patients to either no pacing (DDI at 30 bpm)
or to DDIR pacing at a lower rate of 70 bpm, with
continuation of antiarrhythmic drugs.18 Unexpectedly,
pacing did not prolong the time to the first AF recurrence
(1.9 days vs 4.2 days with no-pacing, P=NS). In fact,
pacing was associated with a trend for higher AF burden.
Potential limitations in this study are the use of a pacing
mode that did not guarantee AV synchrony, the lack of
an overdrive algorithm to ensure a high percentage of
atrial pacing (the atrium is paced in only 67% in this
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study), the use of atrial pacing at the conventional single
site at the RA appendage, and the relatively short followup (10 weeks). In a continuation of this study for those
patients who finally underwent AV nodal ablation, the
DDDR (lower rate 70 bpm) and VDD (lower rate
60 bpm) modes were compared in a randomized
crossover manner with anti-arrhythmic medications
withdrawn.19 Again, the use of atrial pacing at 70 bpm
did not delay the time to the first nor second AF
recurrence, nor in reducing the AF burden. Like other
studies on the atrial rhythm after AV nodal ablation,
permanent AF occurred in 42% of these patients without
antiarrhythmic agents in 1 year.
The PA3 study suggests that in patients who do
not have bradycardia, conventional atrial pacing at
70 bpm used for a short term is not effective in
preventing AF in those with medically refractory AF.

Atrial Overdrive
In patients with conventional pacing with DDDR
pacemaker, it is simple to just increase the backup rate
to suppress AF. Ward et al20 randomized 18 patients
with PAF and SSS to a backup rate of 60, 75 and 90
bpm, each for a 2-month period to test this hypothesis.
While the percentage of atrial pacing increased from
44, 57.5 to 73.5% respectively, the incidence of AF (as
defined by mode switching episodes) were not affected.
On the other hand, one third of the patients developed
angina when programmed at 90 bpm. It seems that the
use of a high fixed lower rate to overdrive the atrium is
not effective and is poorly tolerated.
If a fixed rate is ineffective, perhaps an algorithm
to automatically overdrive the atrium may be more
effective. Table 2 shows the type of algorithms that are

currently available. In the Continuous Atrial Pacing™
algorithm (Medtronic Inc., Minneapolis, MN, USA), for
each P wave sensed the device shortens the atrial escape
interval (e.g. 30 ms) up to a programmable consistent
overdrive rate limit to ensure atrial pacing. In 15 patients
with such an algorithm, the percentage of atrial pacing
is significantly increased from 57% to 86%, the
incidence of APBs reduced, and a trend to a lower
incidence of mode switching and fewer AF symptoms
was observed.21 These benefits were not associated with
a change in the mean atrial rate, both during day and
night time.
In a recently presented trial, Dynamic Atrial
Overdrive (DAO™, St Jude, Minneapolis, MN, USA)
algorithm has been tested in a randomized study on 250
patients. This study, the Atrial Dynamic Overdrive
Pacing to treat paroxysmal AF study (ADOPT-AF) used
the patients' symptoms and event recordings of AF as
endpoints. An episode of AF was assumed to last 1 day,
and AF burden was calculated as a percentage of AF
days over the total duration of follow up. DAO reduced
AF burden (from 60% to 45% after 6 months of pacing)
and improved symptoms of AF. The algorithm was well
tolerated. Similarly, the AFT study (Vitatron, ESC 2001)
also documented that atrial therapies reduce AF
compared to no pacing. Thus if there is evidence of AF
in patients with pacemakers, it is reasonable to activate
an automatic atrial overdrive mechanism that varies its
rate according to the prevailing sinus rhythm rate.

Algorithms Specific to APB Triggers
The ELA introduced an algorithm that shortens
the atrium escape interval in the presence of a sensed
APB that is shorter than 25% of the prevailing sinus

Table 2. Atrial preventive pacing algorithms for AF

Biotronik Inos
Ela Medical Talent DR
Guidant Pulsar Max II
Medtronic AT 500
St Jude Medical Trilogy DR DAO
Vitatron Selection

76

Atrial overdrive
pacing
+
+
+
+
+
+

Response to atrial
premature beats
+
+
+
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Response to end
of mode switch
+
-
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cycle (mean of 8 bests).22 The lower rate is increased
up to 101 bpm, and the duration of overdrive depend
on the APB frequency. In 70 patients, Holter recordings
documented normal functioning of this algorithm, and
a significant reduction of APB frequency. However, the
overall AF frequency was not affected.
After spontaneous or defibrillation-achieved AF
termination, AF could occur in up to 34% of patients.23
Again, closely coupled ectopy is the cause of early reinitiation of AF (ERAF). Tse et al 24 tested, in a
randomized manner, the use of atrial overdrive pacing
post defibrillation in suppressing APBs and ERAF in
12 patients with reproducible ERAF. Pacing at 400 and
300 ms were equally effective in preventing ERAF
(42%), or delaying its onset (58%). APB density was
reduced from 16.4 to 3.4/minute with pacing, and the
mean coupling interval of these APB to sinus rhythm
was significantly prolonged (from 398 to 420 ms by
pacing). "Post-mode-switch" overdrive (Medtronic Inc)
is specifically designed based on this observation. The
efficacy of this algorithm used alone requires further
testing.
A variety of other algorithms such as rate
smoothing post-APBs have been instrumented in
different devices. There is as yet little data on their
efficacy on top of automatic atrial overdrive pacing. In
combination with antitachycardia pacing (ATP), these
algorithms can contribute to reduction of AF burden (see
below).

Alternative and Multiple Site Atrial Pacing
These include pacing at the Bachmann's Bundle
region/interatrial septal pacing, biatrial pacing (RA
appendage and distal CS), and dual site atrial pacing
(RA appendage and low atrial septum).
Bachmann's Bundle Region or Interatrial Septal
Pacing
The existence of the Bachmann's Bundle is
controversial. Nevertheless, acute testing suggests that
pacing at the anterior superior interatrial septum leads
to rapid conduction to either atrium, and may be a
suitable site to suppress AF. In a study of 4 pediatric
patients, transoesphyageal echocardiology was used to
J HK Coll Cardiol, Vol 11

guide the appropriate pacing site. A preliminary good
response was documented. Bailin et al25 randomized 120
patients with a mean age of 70 years either RA
appendage or Bachmann's Bundle region pacing. All
patients had SSS and a history of paroxysmal AF, and
half had a prior AV nodal ablation. The Bachmann's
Bundle region was achieved by positioning an actively
fixed lead in the highest point in the interatrial septum
(using the fluoroscopic left anterior oblique view), with
the lead pointing anteriorly in the right anterior oblique
view. Compared to RA appendage pacing, pacing in
the Bachmann's Bundle region significantly delayed the
onset of permanent AF (75 vs 47% at 1 year, P<0.05).
Interestingly, most cases of permanent AF developed
within 2 months after pacing in the RA appendage
group, thereafter, the onset of permanent AF was similar
between the two groups. Both acute and long term atrial
thresholds were similar between the two pacing sites.
Bachmann's Bundle region pacing was also associated
with a shortened P wave duration. These results are
encouraging. However, there was a high incidence of
AF in the RA appendage group and whether the
concomitant use of anti-arrhythmic drugs would change
the results of the development of permanent AF remains
to be tested. The proximity of the site to the aortic arch
is a potential concern, although no complication related
to the aorta was observed in this study. AF burden was
not measured. Several studies are now underway to test
the addition of dynamic atrial overdrive in suppressing
AF by pacing in the high septal region.
Padeletti et al26,27 reported the results of pacing
in the low interatrial septum. This site was chosen as it
is near the Triangle of Koch (an area of slow
conduction), and was approached by using a screw-in
lead above the CS os. They studied 46 patients with
paroxysmal AF, randomized to either RA appendage
or low septal pacing. Each group was also assessed, in
a crossover manner, with Consistent Atrial Pacing™ (a
form of overdrive suppression) on or off. P wave
duration was significantly reduced compared to sinus
rhythm. Either pacing mode reduced AF compared to
pre-implantation AF frequency, but low interatrial septal
pacing was superior to RA appendage pacing in reducing
AF burden over a 3 month period. Interestingly, the
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atrial overdrive algorithm did not contribute to AF
reduction as observed in other studies.21
Taken together, these studies suggest that pacing
at the interatrial septum (high or low) shortens the
P wave duration, and reduces the incidence of AF
compared to RA appendage site. At least in the shortmedium term, the right interatrial septal site appears to
be as stable and safe as the conventional appendage
position. Barring concern on the complexity in
implantation and long term lead stability, these sites
should be considered a good alternative pacing site in
patients with SSS and PAF.
Biatrial Pacing
Daubert and his colleagues28 pioneered biatrial
pacing by using a CS bipolar lead to achieve left atrial
pacing simultaneously with conventional right atrial
pacing. They tested the efficacy of biatrial pacing in
patients with interatrial conduction delay, as indicated
by a prolonged P wave duration (>120 ms) and interatrial
conduction time (≥100 ms) during electrophysiological
study. In a group of 86 patients, they were able to reduce
P wave duration (from 187±29 to 160±14 ms), and
maintain sinus rhythm in 64% (with 33% free from any
episode of AF). However, in a multicentre European
trial (EHS 1999;20:4), such a benefit was not
reproduced.
Thus this technique may be applicable to select
patients with long interatrial conduction delay, and can
likely contribute also to better left heart AV interval
programming and hemodynamic benefits. However,
double sensing of A and V electrograms in the CS can
be a problem, and special blanking is required. There is
concern (as with biventricular pacing for heart failure)
of the stability of the CS lead, and the ease with which
lead extraction can be effected.
Dual Site Atrial Pacing
Saksena and colleagues29,30 pioneered the use of
RA appendage to RA low septal pacing (just outside
CS os) in suppressing AF. Thirty patients with drug
refractory symptomatic AF with documented primary
or drug-induced bradycardia underwent a crossover
study to assess (1) if pacing was useful to prevent AF
78

compared to pre-implant history; (2) if single site (RA
appendage or CS os pacing) were different and (3) if
dual site pacing had additional benefit to single site
pacing. A fixed rate overdrive was used and event
recorders documented first AF recurrence was used as
the primary endpoint. The mean arrhythmia free interval
was increased from 9±10 days before implant, to
143±110 days during single site periods, to 195±96 days
during dual site cross-over period. The authors did not
find any difference between single site pacing at the
RA appendage or CS os pacing different in suppressing
AF. Significantly, this study also documented long term
safety of dual site pacing up to 3 years, with no case of
CS os lead dislodgement after patient discharge from
hospital, compared to a rate of dislodgement of up to
8% in dual site pacing.31 Although uncontrolled, the long
term efficacy of maintaining sinus rhythm was 78% at
1 year and 56% at 3 years, which was remarkable in a
very refractory group of patients. The limitations of this
study were the lack of an unpaced controlled group,
frequent crossover with potential carryover effect, and
the very frequent changes in anti-arrhythmic medications
made necessary to maintain sinus rhythm.
These early studies prompted several international
randomized trial in this technique. A preliminary report
of the Dutch – DRAPPAF study, showed that dual site
atrial pacing reduced the need for external cardioversion
without changing the AF free interval compared with
the high RA appendage pacing. All patients did not have
associated bradycardia and were paced at 70 bpm. In
another study, Levy et al did not find any difference in
20 patients between single versus dual site pacing, but
they had only examined AF frequency and duration for
1 month in each phase. All patients did not have an
indication for pacing, and the lower rate was fixed at
70 bpm.
We32 have specifically addressed the use of dual
site atrial pacing in patients with paroxysmal AF without
conventional indication for pacing, using pacemakers
with Continuous Atrial Overdrive™ algorithm. Twentytwo patients who had AF recurrence despite sotalol
underwent randomized crossover periods of 12 weeks
with either pacing on (and sotalol) or continuation of
sotalol only. The endpoints were event recorder
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documented AF recurrence and pacemaker memory of
AF burden. Dual site atrial pacing increased the
percentage of atrial pacing (13±18 to 80±30%), reduced
the number of APBs (8265 to 2740/day), prolonged the
time to the first documented AF (symptomatic or
asymptomatic), and reduced AF burden (45±34 to
22±29%) as monitored by pacemaker memory. Pacing
reduced the risk of AF recurrence by 3.2 times. There
was significant change in some measures of quality of
life, but no significant change in overall symptoms. The
DAPPAF (Dualsite Atrial Pacing for the Prevention of
AF) prospectively randomized and crossover patients
between dual site and RA appendage pacing and support
pacing in patients with PAF and pacing indications. The
preliminary results suggested that dual site pacing with
overdrive in combination with either Class 1 or 3
antiarrhythmic agents was better tolerated and more
effective in AF prevention than overdrive RA pacing
or support pacing.33
Taken together, these trials indicate that pacing
has effect on the burden of AF in patients with or without
the need of a pacemaker. Automatic atrial overdrive
pacing is necessary for pacing to be effective, and
multisite pacing has an incremental benefit. However,
the relatively small change is symptoms compared to
AF burden reduction may suggest that the use of
multiple leads (with their complexity of implantation
and programming) should probably be reserved to those
with moderate severity of AF. It remains uncertain the
clinical profile that will predict a response to dual site
atrial pacing. Neither the P wave duration nor interatrial
delay before pacing were predictive of an effective
outcome.34

patient). Beta-blockers and amiodarone have been
shown to be effective prophylactic agents for AF, but
AF still developed in up to 30% of these patients despite
amiodarone pre treatment.35
After cardiac surgery, epicardial pacing
placement is often a routine for support pacing, and it
is of interest to assess if pacing may have some effects
on post operative AF. Several studies have recently
examined the effect of pacing (on top of a beta-blocker)
in suppressing post-operative AF. Fan et al36 randomized
132 patients to biatrial, RA, and left atrial pacing or
control. Manual overdrive atrial pacing was performed
for 5 days, at 10 bpm above the intrinsic rate up to 90
bpm. Only biatrial pacing reduced the development of
sustained AF (42% in control to 12.5% during pacing),
whereas single site pacing had no effect. The beneficial
effect was attributable to a larger reduction of P wave
dispersion during biatrial pacing compared with single
site pacing or control, and only patients with AF
prevention had a reduction in P wave duration. Post
operative intensive care stay and the associated cost
were reduced. Daoud et al37 also showed significant
reduction of AF in overdrive biatrial pacing versus RA
pacing in post operative patients, and overdrive RA
pacing was not better than RA support pacing. On the
other hand, Greenberg et al38 did not show benefit of
either RA or biatrial pacing in suppressing AF in 65
patients. There was a low usage of betablockers in this
study. Some of the discrepancies may be related to the
method of atrial overdrive (manual or automatic), and
the site of left atrial lead itself (Posterior aspect of left
atrium is the usual site). However, the convenience and
ease of instrumentation of biatrial pacing would be a
strong incentive to apply this technique to most patients
after post operative cardiac surgery.

AF after Cardiac Surgery
Approximately 20% of patients developed AF
after bypass surgery. The causes are multifactorial, and
may include the effects of cardiac bypass, changes in
sympathetic tone and post operative infection. The
development of AF is associated with an increase in
stroke, heart failure and length of hospital stay, and
substantially increase management cost (US$11,000/
J HK Coll Cardiol, Vol 11

Antitachycardia Pacing
While the short excitable gap during sustained
AF does not lend itself for pacing termination, antitachycardia pacing (ATP) have several potential
mechanisms to reduce AF burden. A significant number
of episodes of AF degenerate from atrial tachycardia or
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flutter, and early termination of these precursor rhythms
may prevent AF to become established. Conversely,
after anti-arrhythmic agents (especially class Ic drugs),
AF may be converted to flutter (Ic flutter) or a slower
AT that can be terminated. It is logical to consider ATP
in an implanted device to terminate these AF related
rhythms.
Atrial ATP (burst, ramp and 50 Hz stimulation)
has been instrumented in a combined atrial and
ventricular ICD (Jewel AF, Medtronic Inc). Several
groups have reported on the efficacy of ATP, ranging
from 33% to 86%. Israel CW stored atrial electrogram
to classify the regularity of AT, suggested that organized
AT with cycle length >200 ms were more likely than
those faster and less well organized ones to be terminated
(59% vs 6%). Interestingly, "organized" AT rhythms
were encountered in nearly half of all recorded episodes
in patients with a clinical diagnosis of paroxysmal AF,
suggesting that ATP may have a role in these patients.
25% of patients with ICDs have associated AF. Friedman
et al39 randomized 52/269 patients with Jewel AF to
either ATP, (defibrillation) and preventive pacing versus
only ventricular ICD function, each for a 3 month
randomized period. Atrial therapies significantly
reduced AF burden from 58.5 to 7.8 h/months. The
efficacy of ATP for terminating slower and faster atrial
tachyarrhythmias were 62 and 49% respectively.
Patients with long episodes were more likely to have
burden reduction than those who had short episodes,
and these patients tended to have better ejection fraction.
In these studies, significant number of patients recruited
were excluded from analysis, such as due to protocol
violation, inadequate atrial electrogram recording. In
addition, the use of antiarrhythmic medications was
difficult to be standardized. Further, the efficacy of ATP
may be under-estimated as the current algorithms do
not allow reactivation of ATP when the initial attempts
fail. It is uncertain if burden reduction was related to
pacing prevention or to ATP itself. A recent study40
tested the effect of atrial overdrive pacing and
termination algorithm in 324 patients with the AT500
device (Medtronic Inc). It was found that the termination
algorithm is effective in 54% of episodes, but did not
significantly reduce the burden of AF.
80

Ventricular Rate Stabilization
Apart from a rapid rate, irregularity in AF
contributed to an abnormal cardiac hemodynamics.41,42 By
pacing the RV at a rate slightly faster than the mean
ventricular rate of AF, it is possible to suppress shorter
cycles and regularize the rate.43 This has been attributed
to retrograde concealed activation in the AV node. In
13 patients with a VVI pacemaker and permanent AF,44
pacing rate at 10 bpm above the mean ventricular rate
suppressed all intrinsic beats. On the other hand, pacing
was less effective during low level of exercise, but
regularity index was still significant better and cardiac
output improved by 7%. Ventricular rate stabilization
algorithms have been instrumented by several
manufacturers. While clinical benefit in the ambulatory
patients remained to be confirmed, it is easy to
instrument and will probably become an accepted
pacing technology in all pacemaker patients who
develop AF.

Future Perspectives
Pacing either in the treatment or prevention of
AF should not be an isolated therapy. AF is a
heterogeneous disease, and a hybrid approach is the
standard. For example, concomitant antiarrhythmic
medications are commonly used with pacing.
Radiofrequency ablation can eliminate pulmonary vein
ectopic foci for AF or modify the atrial substrate, and
atrial defibrillation can further enhance that maintenance
of sinus rhythm. The various types of hybrid therapy
are under evaluation.
An important development in device therapy for
AF is the ability to measure the total amount of AF (AF
burden) that can be confirmed with stored atrial
electrograms. This is a more accurate assessment of AF
than the time to the first recurrence of AF itself. In
addition, device-based AF recording gives the clinicians
the possibility of objectively measuring the severity of
AF, and may become a useful guide to assess
interventional procedures, the need of anticoagulation,
and to understand the symptomatology of AF itself.
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Conclusion
Ablate and pace for medically refractory AF is
clinically proven, and is an effective symptomatic
therapy. In patients with SSS, an atrial based pacemaker
should be prescribed to reduce future episodes of AF.
An automatic atrial overdrive algorithm appears to be
effective in reducing symptomatic AF. Dual site right
atrial pacing, in the presence of overdrive and beta
blocker confers additional benefit to single site pacing.
Epicardial biatrial pacing is a useful technique to reduce
the incidence of AF complicating cardiac surgery. While
automatic mode switching and ventricular rate
stabilization will become programmable features of
modern pacemakers, the role of ATP in patients with
AF remains to be confirmed. It is likely that pacing
efficacy will be enhanced when combined with the
strategies such as ablation, pharmacotherapy and
defibrillation.
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